GSK3B and cancer: In the OTSCC progression model, a total of twenty-two samples were analyzed, and GSK3β overexpression was observed in 14.2% (1/7) of normal samples, in 20.0% (1/5) of hyperplasia and 70.0% (7/10) of cancer samples (p = 0.0396).